Suppr超能文献

未经治疗的格雷夫斯病患者的全血细胞减少症。

Pancytopenia in untreated patients with Graves' disease.

作者信息

Lima Carmen S P, Zantut Wittmann Denise E, Castro Vagner, Tambascia Marcos A, Lorand-Metze Irene, Saad Sara T O, Costa Fernando F

机构信息

Hematology and Hemotherapy, Department of Internal Medicine, State University of Campinas, Campinas, São Paulo, Brazil.

出版信息

Thyroid. 2006 Apr;16(4):403-9. doi: 10.1089/thy.2006.16.403.

Abstract

Severe pancytopenia is a rare but severe complication of thyrotoxicosis. In this report, we describe four patients with Graves' disease who presented with pancytopenia at diagnosis. Methimazole (30-40 mg/d) or propylthiouracil (400 mg/d) restored normal hematopoiesis in three of the patients. The remaining patient evolved to aplastic anemia under therapy with methimazole (60 mg/d), but had an increased peripheral blood count that almost reached normal values after radioiodinetherapy and standard immunosuppressive treatment with antithymocyte globulin (700 mg/d, intravenous infusion for 5 days), oral cyclosporin (400 mg/d), prednisone (30-60 mg/d), and granulocyte colony-stimulating factor (150 microg subcutaneous injection, 3 times per week). We conclude that: (1) a hematologic evaluation of all patients with Graves' disease should be performed before administering antithyroid drugs, (2) antithyroid drugs may be administered to patients with pancytopenia and bone marrow hypercellularity but a reevaluation of the bone marrow must be done if there is no recovery of the peripheral blood cell count when euthyroidism state is achieved, (3) standard immunosuppressive treatment of aplastic anemia caused by antithyroid drugs restores normal hematopoiesis, and (4) a thyroid evaluation of patients with pancytopenia should be done, even though no related symptoms are found.

摘要

严重全血细胞减少是甲状腺毒症罕见但严重的并发症。在本报告中,我们描述了4例Graves病患者,他们在诊断时出现全血细胞减少。甲巯咪唑(30 - 40mg/d)或丙硫氧嘧啶(400mg/d)使其中3例患者的造血恢复正常。其余1例患者在接受甲巯咪唑(60mg/d)治疗过程中发展为再生障碍性贫血,但在放射性碘治疗以及使用抗胸腺细胞球蛋白(700mg/d,静脉输注5天)、口服环孢素(400mg/d)、泼尼松(30 - 60mg/d)和粒细胞集落刺激因子(150μg皮下注射,每周3次)进行标准免疫抑制治疗后,外周血细胞计数增加,几乎达到正常水平。我们得出以下结论:(1)在给予抗甲状腺药物之前,应对所有Graves病患者进行血液学评估;(2)对于全血细胞减少且骨髓细胞增多的患者可给予抗甲状腺药物,但如果在达到甲状腺功能正常状态时外周血细胞计数未恢复,则必须重新评估骨髓情况;(3)对抗甲状腺药物所致再生障碍性贫血进行标准免疫抑制治疗可恢复正常造血;(4)即使未发现相关症状,也应对全血细胞减少患者进行甲状腺评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验